Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2537

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Chemical structure diagram of Duloxetine hydrochloride, showing its molecular framework including a naphthyl group, a thiophene ring, and a methylamino side chain with hydrochloride.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares relapse rates between placebo and duloxetine treatment groups, with relapse proportion on the y-axis and time in days on the x-axis, illustrating that the duloxetine group has a consistently lower relapse proportion than the placebo group over approximately 200 days.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

Kaplan-Meier survival curve showing the proportion of patients with relapse over time from randomization to relapse in days, comparing Duloxetine versus placebo. The graph indicates a lower proportion of relapse in patients treated with Duloxetine compared to placebo over approximately 250 days.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

A line graph showing the percentage of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares results for Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and a placebo group.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The graph compares efficacy based on varying levels of pain improvement.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement trends across different pain reduction thresholds.*

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

A line graph showing the percentage of patients improved at various levels of percent improvement in pain from baseline, comparing four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two markers), and placebo. The y-axis represents the percentage of patients improved, while the x-axis shows increasing percent improvement in pain from baseline ranging from greater than 0 to 100.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

A line graph showing percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percentage of patients improved (0 to 100%). Two groups are compared: Duloxetine 60 mg once daily and placebo, with Duloxetine showing higher percentages of patients improved across pain relief thresholds.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline, showing data for Duloxetine 60/120 mg once daily and placebo. The y-axis represents the percentage of patients improved, while the x-axis represents percent improvement in pain. Duloxetine shows higher patient improvement percentages than placebo across most levels of pain improvement.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for placebo and duloxetine 60 mg once daily. The graph shows two lines with data points depicting the response to placebo versus duloxetine treatment over various thresholds of pain improvement.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare Placebo and Duloxetine 60/120 mg once daily, with the Duloxetine group consistently showing higher percentages of patient improvement across various pain improvement thresholds.*

FDA Label Image

Label (Lbl713352537)

Label for Duloxetine 30 mg delayed-release capsules by Bryant Ranch Prepack. The label includes dosage form as capsules, NDC 71335-2537-1, manufacturer Lupin Limited, and a package size of 30 capsules. It states the active ingredient strength and storage instructions, along with barcode and QR codes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.